Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting

Liver International : Official Journal of the International Association for the Study of the Liver
Giovanni PerriconeEuropean Liver and Intestine Transplant Association (ELITA)

Abstract

Treating patients with decompensated cirrhosis with direct-acting antiviral (DAA) therapy while on the waiting list for liver transplantation results in substantial improvement of liver function allowing 1 in 4 patients to be removed from the waiting list or delisted, as reported in a previous study promoted by the European Liver and Intestine Transplant Association (ELITA). The aim of this study was to report on clinical outcomes of delisted patients, including mortality risk, hepatocellular carcinoma development and clinical decompensation requiring relisting. One hundred and forty-two HCV-positive patients on the liver transplant waiting list for decompensated cirrhosis, negative for hepatocellular carcinoma, between February 2014 and June 2015 were treated with DAA therapy and were prospectively followed up. Forty-four patients (30.9%) were delisted following clinical improvement. This percentage was higher than in the original study because of a number of patients being delisted long after starting DAAs. The median Child-Pugh and MELD score of delisted patients was 5.5 and 9 respectively. Four patients were relisted, because of HCC diagnosis in 1 case and 3 patients developed ascites. One further patient died (2.4%) becaus...Continue Reading

References

Jan 30, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jeong Won JangKwang-Hyub Han
May 24, 2016·Journal of Hepatology·Luca Saverio BelliUNKNOWN European Liver and Intestine Association (ELITA)
Dec 25, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jennifer A FlemmingNorah A Terrault
Aug 27, 2017·Journal of Hepatology·Juan Manuel PascasioMaría-Carlota Londoño

❮ Previous
Next ❯

Citations

Mar 23, 2019·Future Microbiology·Gema LledóCarmen de Mendoza
Jan 23, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Giuseppe Indolfi, Edoardo G Giannini
Aug 28, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Elena CampelloPaolo Simioni
Jun 27, 2019·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Lourdes Domínguez DomínguezFederico Pulido
Dec 5, 2020·Journal of Hepatology·Francesco Negro
Nov 20, 2020·Journal of Hepatology·Kelley Weinfurtner, K Rajender Reddy
May 2, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ming-Lung YuWan-Long Chuang
Sep 22, 2020·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.euUNKNOWN Panel members:
Sep 25, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Therese Bittermann, K Rajender Reddy
May 1, 2021·Clinics and Research in Hepatology and Gastroenterology·Ekaterina A NabatchikovaSergey V Moiseev
Jun 18, 2021·World Journal of Gastroenterology : WJG·Stella CompagnoniSalvatore Madonia
Aug 28, 2021·World Journal of Gastroenterology : WJG·Tiffany KhooJohn K Olynyk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.